0GA.F Predilife SA
- Market cap
- EUR 2.68M
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 0GA.F undervalued?
Graham numberThe Graham number of Predilife SA cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Predilife SA fundamental analysis
No fundamental analysis for Predilife SA yet.
Predilife SA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Predilife SA
Predilife S.A. designs and markets predictive tests for the occurrence of serious illnesses. It provides breast cancer predictive assessment; and multi-pathology predictive assessment. The company also offers MammoRisk, a breast cancer prediction test based on the patient's individual risk; and DenSeeMammo, a breast density measurement software. Predilife S.A. was incorporated in 2004 and is headquartered in Villejuif, France.
Full company profilePredilife SA financial statements
Predilife SA annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 143K | 289K | 318K | 493K | 836K |
| Gross Profit | 93.4K | 252K | 307K | 471K | 820K |
| Operating Income | -3.51M | -3.50M | -3.84M | -4.00M | -3.27M |
| EBITDA | - | -3.48M | -3.82M | -3.71M | -3.20M |
| Net Income | -3.40M | -3.65M | -4.22M | -4.26M | -3.93M |
| EPS | -0.93 | -1.00 | -1.14 | -1.14 | -1.00 |
| Balance Sheet | |||||
| Total Assets | 3.97M | 9.17M | 4.39M | 2.44M | 1.83M |
| Total Liabilities | 5.53M | 8.21M | 8.31M | 6.71M | 8.75M |
| Shareholders' Equity | -1.57M | 957K | -3.92M | -4.27M | -6.91M |
| Cash & Short-term Investments | 2.82M | 3.72M | 2.51M | 1.06M | 557K |
| Cash Flow | |||||
| Operating Cash Flow | -3.83M | -3.07M | -4.23M | -3.72M | -2.56M |
| Capital Expenditure | 3.37K | 27.0K | 42.4K | 5.40K | 2.03K |
| Free Cash Flow | -3.83M | -3.09M | -4.27M | -3.73M | -2.57M |
| Ratios | |||||
| ROE | - | -381.0% | - | - | - |
| ROA | -85.8% | -39.8% | -96.0% | -174.5% | -214.6% |
| Net Profit Margin | -2,385.6% | -1,262.9% | -1,326.7% | -864.7% | -470.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Predilife SA dividends
Predilife SA has not paid dividends in the last 5 fiscal years.
Who owns Predilife SA
- Insiders 50.95%
- Institutions 0.00%
- Public & others 49.05%
- Shares outstanding 3.94M
Predilife SA company profile
- Company name
- Predilife SA
- Ticker
- 0GA.F
- ISIN
- FR0010169920
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Employees
- 20
- Fiscal year end
- December
- Address
- 39 Rue Camille Desmoulins, Villejuif, France, 94805
- Phone
- 33 9 72 22 67 08
- Website
- predilife.com
About Predilife SA
Predilife S.A. designs and markets predictive tests for the occurrence of serious illnesses. It provides breast cancer predictive assessment; and multi-pathology predictive assessment. The company also offers MammoRisk, a breast cancer prediction test based on the patient's individual risk; and DenSeeMammo, a breast density measurement software. Predilife S.A. was incorporated in 2004 and is headquartered in Villejuif, France.
Predilife SA management
2- Mr. Stephane RagusaFounder, President, CEO & Chairman · born 1970
- Mr. Émilien GauthierChief Technical Officer